Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes

NCT01855087 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2013-05-16

No results posted yet for this study

Summary

There is paucity of information about the combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin and insulin. This study aimed to retrospectively investigate the safety and efficacy of this therapeutic modality in Japanese patients with type 2 diabetes.

Conditions

Sponsors & Collaborators

  • The Japan Kidney Foundation

    collaborator OTHER
  • Kanagawa Physicians Association

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2013-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01855087 on ClinicalTrials.gov